Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + Lenalidomide vs Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (AURIGA)
NCT03901963Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2019
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Minimal Residual Disease Conversion Rate at 12 months. Started Apr 2019; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03901963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03901963.